Membership is open to all those with an interest in the quality and integrity of scientific research and development and those working with, or interested in, Good Laboratory, Clinical or Manufacturing Practice regulations or Pharmacovigilance, be they from industry, government, academia or contract research and wherever in the world they are based.
Welcome to the RQA website
The Association has changed its name from BARQA to the Research Quality Association (RQA).
As an Association dedicated to informing and advancing its members, we provide status and visibility for individuals concerned with the quality of research in pharmaceutical, agrochemical and chemical industry sectors. Since its beginnings in 1977, the Association has grown and developed to reflect regulatory changes, the impact of regulatory inspection and the changing structure and needs of industry. Click here to view our vision and mission statement.
RQA Annual General Meeting 2013
The RQA AGM will be held on the 6th November 2013 at the National Motorcycle Museum, Solihull, West Midlands. The meeting will take place at 12.00hrs and all RQA members are welcome. The AGM will be held in conjunction with a number of seminars at the same location, thereby allowing those elegible seminar delegates to attend the AGM also.
Seminars are currently being developed by the following Committees - Good Laboratory Practice, Computing, Medical Devices, Good Clinical Practice and Pharmacovigilance. Details on these seminars will be available soon.
1st European QA Conference, Bonn, Germany - September 2013
Delegate registration is now open for the conference. Please visit www.european-qa-conference.com for all the information and the full conference programme.
If you have previously subscribed to the BARQA RSS feeds, please ensure you update your reader with the.
Latest News Items
Revised code of GMP for human blood and tissues
The Therapeutic Goods (Manufacturing Principles) Determination No. 1 of 2013 references the Australian Code of Good Manufacturing Practice for human blood and blood components, human tissues and human cellular therapy products 2013 (2013 Code of GMP). These requirements commence from 31 May 2013.
New requirements for active substances imported into the European Economic Area
The Falsified Medicines Directive 2011/62/EU ("the FMD") modifies EU Medicines Directive 2001/83/EC and from 2ndJuly 2013 introduces new requirements for active substances (ASs) imported into the European Economic Area (EEA) for use in the manufacture of authorised medicinal products.